Analyst Ratings for Cubist Pharmaceuticals (CBST) [Buys]
CBST Rating Summary
CBST Price Target Summary
- Highest: $68.00 (Morgan Stanley)
- Lowest: $5.00 (ThinkEquity)
- Average: $49.55
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$49.55 (-2.4%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/3/2013 | UBS | New Coverage | Buy (N/A) |
61.00 (N/A) |
46.15 | 50.77 | 10.01% | Details |
| 10/4/2012 | Morgan Stanley | New Coverage | Overweight (N/A) |
68.00 (N/A) |
48.48 | 50.77 | 4.72% | Details |
| 8/8/2012 | Goldman Sachs | New Coverage | Conviction Buy (N/A) |
54.00 (N/A) |
43.49 | 50.77 | 16.74% | Details |
| 7/20/2012 | Caris & Co. | Downgrade | Above Average (Buy) |
N/A (N/A) |
40.63 | 50.77 | 24.96% | Details |
| 3/23/2012 | ThinkEquity | New Coverage | Buy (N/A) |
5.00 (N/A) |
43.61 | 50.77 | 16.42% | Details |
| 4/20/2011 | Oppenheimer » Updated 10/17/2012 |
Upgrade | Outperform (N/A) |
55.00 (49.00) |
31.66 | 50.77 | 60.36% | Details |
| 4/5/2011 | Lazard Capital | Upgrade | Buy (N/A) |
N/A (N/A) |
25.25 | 50.77 | 101.07% | Details |
| 4/5/2011 | Wedbush » Updated 10/20/2011 |
Upgrade | Outperform (N/A) |
50.00 (N/A) |
25.25 | 50.77 | 101.07% | Details |
